NCT06283576

Pancreatic Cancer Initial Detection Via Liquid Biopsy

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Karolinska University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

Conditions

• Pancreatic Cancer
• IPMN, Pancreatic
• Individuals at Risk
• Chronic Pancreatitis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Liquid biopsy	Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for "ground truth"

Timeline

• Start date: 2024-05-01
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2024-02-28
• Last updated: 2024-04-24

Locations

1 site across 1 country: Sweden